GO
Loading...

Enter multiple symbols separated by commas

Search results for "TEVA"

REFINE RESULTS

SEARCH RESULTS

About 134 results. Sort By: Date | Relevance
Trades to wrap up a volatile week

The "Halftime Report" traders give their trades for the second half of the day.
Source: CNBC.com | By: Stephanie Landsman
Pfizer mystery bidder for drugmaker Sobi: Sources

Pfizer is the mystery bidder for Sobi, the rare disease specialist which disclosed that a potential buyer had made a preliminary offer, sources said.
Source: Reuters
4 Internet stocks to buy on earnings moves

"Fast Money" traders discussed how to play LinkedIn's battering and FireEye's pop in post-earnings trading.
Source: CNBC.com | By: Jacob Pramuk
Your first trade for Friday

The "Fast Money" traders give their final trades of the day.
Source: CNBC.com | By: Stephanie Landsman
Biotech bust may be sending message about stocks

Traders are watching the iShares Nasdaq Biotechnology ETF for clues on whether a deeper stock market decline is on the horizon.
Source: CNBC.com | By: Patti Domm
Trades to go as April winds down

The "Halftime Report" traders give their trades for the second half.
Source: CNBC.com | By: Stephanie Landsman
EXCLUSIVE-Pfizer is mystery bidder for rare disease drugmaker Sobi -sources

NEW YORK/ LONDON, April 30- Pfizer Inc is the mystery bidder for Swedish Orphan Biovitrum AB, the rare disease specialist which disclosed this week that a potential buyer had made a preliminary offer, people with knowledge of the situation said. Sobi did not identify its potential acquirer when it revealed on Monday that it had received an approach, but Biogen and...
Source: Reuters | By: Olivia Oran, Ben Hirschler and Pamela Barbaglia
UPDATE 2-Teva lifts 2015 earnings forecast as pursues Mylan bid

*Q1 adjusted EPS $1.36 vs $1.25 forecast. *Raises 2015 adjusted EPS forecast to $5.05- $5.35. TEL AVIV, April 30- Teva Pharmaceutical Industries raised its 2015 earnings forecast after beating first-quarter estimates, and said it would devote "all necessary resources" to its $40 billion- plus bid for rival Mylan Inc..
Source: Reuters | By: Tova Cohen
UPDATE 1-Teva lifts 2015 earnings view after better than expected Q1

*Q1 adjusted EPS $1.36 vs $1.25 forecast. *Raises 2015 adjusted EPS forecast to $5.05- $5.35. TEL AVIV, April 30- Teva Pharmaceutical Industries, which is seeking to acquire rival Mylan Inc for over $40 billion, raised its full-year earnings outlook after posting a bigger-than-expected increase in first-quarter profit.
Source: Reuters
Market digs for next clue for data dependent Fed

The markets quickly shifted focus from the Fed meeting to the upcoming April jobs report, as the next possible source of clues on rate hikes.
Source: CNBC.com | By: Patti Domm